Patients and methods: one hundred and sixty gastric cancer patients were assessed HER2 / neu overexpression by IHC using PATHWAY anti-HER-2 / neu (4B5) kit and were assessed HER2 / neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit with biopsy specimens.